

CERTIFICATE OF ELECTRONIC FILING

Benjamin L. Volk, Jr.  
Reg. No. 48,017

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

Group Art Unit: 3626

## Reply Brief

At page 42, the Examiner's Answer alleges that various arguments from the Appeal Brief which are based on a distinction between "retail pharmacies" and "closed pharmacies" are not pertinent to the patentability of the claims. (See, e.g., Amended Appeal Brief; p. 5-6; 21-25).

In response to applicant's arguments that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., distinction between closed pharmacies and retail pharmacies) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. (See Examiner's Answer; p. 42).

Applicant strongly disagrees. Independent claims 1, 30, and 62 specifically require that a retail pharmacy be involved as a buyer.<sup>1</sup> Applicant respectfully submits that the claim limitation “retail pharmacy”, even when given its broadest reasonable meaning, cannot be reasonably interpreted to mean a “closed pharmacy”. The term “closed pharmacy” is defined by Applicant in the specification as follows:

**A closed pharmacy** is a pharmacy that supplies pharmaceuticals to institutions such as hospitals or nursing homes, **but does not sell pharmaceuticals to walk-in customers**. (See Patent Application; p. 3, lines 11-13 (emphasis added)).

Thus, the term “closed pharmacy” specifically excludes a pharmacy that sells pharmaceuticals to walk-in customers. By contrast, Applicant respectfully submits that the claim limitation “retail pharmacy” must be interpreted at least in part to require that the retail pharmacy sell pharmaceuticals to walk-in customers. Such an interpretation is consistent with the usage of the term “retail pharmacy” in the specification. (See Patent Application; p. 3, lines 21-22 (noting that retail pharmacies “also supply pharmaceuticals to walk-in customers”)). As such, Applicant respectfully submits that any interpretation of the claim limitation “retail pharmacy” by the Examiner which would encompass a “closed pharmacy” is inappropriate because such an interpretation would be repugnant to its ordinary meaning and inconsistent with the usage of those terms in the specification.

Moreover, Applicant respectfully submits that this misunderstanding of the terms “retail pharmacy” and “closed pharmacy” by the Examiner is directly related to the Examiner’s failure to recognize the patentability of independent claims 1, 30, and 62 over the cited

---

<sup>1</sup> For example, independent claim 1 specifically recites that the buyer comprises “one from a group consisting of (1) an entity comprising at least one retail pharmacy that supplies pharmaceuticals to at least one nursing home, and (2) at least one retail pharmacy that supplies pharmaceuticals to at least one nursing home”. Independent claim 30 specifically recites that the software executed by the processor be configured to “confirm whether said buyer is any of a group consisting of (a) an entity comprised of at least one retail pharmacy that supplies pharmaceuticals to at least one nursing home, and (b) at least one retail pharmacy that supplies pharmaceuticals to at least one nursing home”. Independent claim 62 specifically recites that “said buyer comprises at least one selected from the group consisting of (1) a retail pharmacy that supplies pharmaceuticals to at least one hospital, nursing home, or long term health care facility where said at least one patient resides, and (2) an entity comprising a plurality of said retail pharmacies”.

references. Page 3 of the patent application provides background information as to the problem solved by the invention of claims 1, 30, and 62.

Currently, in the United States ..., approximately 55% of nursing homes purchase their pharmaceuticals from "closed pharmacies." A closed pharmacy is a pharmacy that supplies pharmaceuticals to institutions such as hospitals or nursing homes, but does not sell pharmaceuticals to walk-in customers. ***Because these closed pharmacies have an exclusive customer list of customers who are eligible to buy pharmaceuticals at an "own use" discount, pharmaceutical manufacturers are willing to sell pharmaceuticals to these closed pharmacies at a discounted price.*** That is, pharmaceutical manufacturers are not overly worried that the "closed pharmacy" will sell discounted pharmaceuticals at a regular price to customers ineligible for a discount, because the "closed pharmacy" has virtually no such customers.

However, approximately 45% of nursing homes are served by retail pharmacies. These retail pharmacies, in addition to supplying the pharmaceutical needs of a nursing home, also supply pharmaceuticals to walk-in customers. Thus, when a retail pharmacy purchases drugs from a pharmaceutical manufacturer or a pharmaceutical distributor, the retail pharmacy may be purchasing pharmaceuticals on behalf of not only the nursing home, but also its walk-in customer trade. ***Because these retail pharmacies are supplying pharmaceuticals to walk-in customers as well as nursing homes, pharmaceutical manufacturers have been unwilling to sell "own use" discount pharmaceuticals to such retail pharmacies for fear of diversion.*** ... As a result, some 7,648 nursing homes (approximately 45% of all nursing homes) pay more money than necessary when purchasing pharmaceuticals. (See Patent Application; p. 3, line 9- p. 4, line 2 (emphases added)).

Against this backdrop, Applicant asserts that the pharmacies described in the Colella reference are not retail pharmacies, but rather "closed pharmacies". This is apparent from the Colella reference when it explains the problem its system seeks to solve:

It has been known for health care providers, such as hospitals, to have ***a pharmacist or pharmacy department within the hospital*** to coordinate the dispensing of drugs to the patients of the health care institution. The pharmacists ***in such health care institutions*** have long been burdened with the increasingly complex record keeping and inventory management that results from hospitals caring for hundreds, if not thousands of patients every day. (See Colella; col. 1, lines 12-20 (emphasis added)).

Thus, Applicant respectfully submits that a person having ordinary skill in the art who reads the Colella reference would understand that Colella's "pharmacy department within the hospital" is a "closed pharmacy" (meaning that the in-hospital pharmacy would not serve the

pharmaceutical needs of walk-in customers). To alleviate the inventory management and record-keeping burdens for such closed pharmacies, Colella discloses a distributed system for tracking pharmaceutical usage within a hospital and leveraging this usage tracking to stay current on assembling orders for new pharmaceuticals to refill the pharmacy shelves. No aspect of Colella addresses the distribution of pharmaceuticals to walk-in customers. For example, Applicant finds no disclosure in Colella of a system that would track distributions of pharmaceuticals to walk-in customers. Thus, when the Examiner's Answer contends that Colella discloses processing pharmaceutical orders for a buyer, wherein the buyer comprises a retail pharmacy or an entity comprising at least one retail pharmacy (see Examiner's Answer at p. 6), Applicant respectfully submits that this assertion is completely erroneous.

Most telling, Colella in no way addresses the concept of placing orders for pharmaceuticals for which the price is reduced by an "own use" discount. Applicant respectfully submits this silence further confirms the fact that Colella addresses closed pharmacies within hospitals for which no question exists in the minds of pharmaceutical sellers as to their entitlement to the "own use" discount.

Moreover, the Gardner reference that is relied upon by the Examiner for teachings relating to the "own use" discount actually teaches hospitals to monitor their pharmacy practices to ensure that brokers and business enterprises which serve retail pharmacies such as "small drugstores" do not receive "own use"-discounted pharmaceuticals from the hospital's inventory. Thus, Applicant respectfully submits that Gardner teaches away from the invention defined by claims 1, 30, and 62 because Gardner teaches the use of monitoring and auditing practices that are designed to prevent "own use"-discounted pharmaceuticals from ever reaching retail pharmacies.

In stark contrast, the invention defined by claims 1, 30, and 62 constitutes a new, useful, and nonobvious invention that conducts an audit on a buyer's pharmaceutical needs to make it possible for "own use"-discounted pharmaceuticals to reach retail pharmacies – a result that Gardner seeks to avoid and that Colella has no capability of achieving.

The Examiner's Answer also repeatedly mischaracterizes the arguments in Applicant's Appeal Brief as attacking the cited references individually rather than the prior art combination as a whole. (See Examiner's Answer, e.g. at p. 40, 41, and 43). However, Applicant's

arguments on appeal do in fact address the asserted prior art combination as a whole. These arguments establish that the Colella and Gardner references, when considered in combination as a whole, would lead a person having ordinary skill in the art to employ Colella's pharmaceutical inventory monitoring and management system to audit a closed pharmacy's practices to detect whether any pharmaceuticals within that closed pharmacy's inventory (which have presumably already been purchased at an "own use" discount) are being diverted to questionable brokers/business enterprises. Thus, the prior art combination cited by the Examiner addresses a post-purchase audit of pharmaceuticals which have already received an "own use" discount to assess whether those pharmaceuticals are being diverted to questionable brokers/business enterprises. By contrast, the invention defined by independent claims 1, 16, 30, 62, 69, 75, and 76 addresses a pre-purchase audit of a pharmaceutical purchase order to assess whether that purchase order qualifies for an "own use" discount. Such an invention is not rendered obvious by the Colella/Gardner reference, as explained in the Amended Appeal Brief.

With respect to other comments found in the Examiner's Answer, Applicant notes the following:

- As to the rejection of claim 69 under 35 USC 112, first paragraph, Applicant notes that the Examiner's Answer fails to address any of the case law cited by Applicant in the Amended Appeal Brief. The Examiner's rejection of claim 69 is predicated upon the Examiner's interpretation of the claim term "a computer configured to ..." as a "means plus function" limitation. Rather than responding to Applicant's citation and discussion of specific case law addressing the use of the term "computer" in a claim, the Examiner's Answer mistakenly relies on case law from the biotechnical field where the claim term "computer" was not involved. As such, for the reasons expressed in the Amended Appeal Brief, Applicant respectfully submits that the rejection of claim 69 is erroneous.
- With respect to the rejections of claims 37, 43, and 44 under 35 U.S.C. 112, second paragraph for indefiniteness, Applicant notes that the Examiner's Answer fails to address any of the case law cited by Applicant in


the Amended Appeal Brief in which the use of a relative term such as "sufficient" was not found indefinite because of the guidance provided in the specification as to the meaning of such a term. In the Amended Appeal Brief, Applicant pointed out specific passages in the specification that provide an understanding to one of ordinary skill in the art as to what would be a "sufficient number of matches." (See Amended Appeal Brief; p. 14-16). The Examiner's Answer fails to address the specific paragraphs of the specification cited by Applicant and instead has merely repeated the unsupported conclusion that "the specification does not provide a standard." (See Examiner's Answer; p. 39).

Thus, for the reasons expressed herein and in Applicant's Amended Appeal Brief, Applicant respectfully submits that the Examiner's rejections as to all pending claims in this patent application are in error and must be reversed. Favorable action is respectfully requested.

Respectfully submitted,

**Thompson Coburn LLP**

By:

  
Benjamin L. Volk, Jr.  
Reg. No. 48,017  
One US Bank Plaza  
St. Louis, MO 63101-1693  
(314) 552-6000  
(314) 552-7000 (fax)